Con más de 200 patologías asociadas, incluyendo enfermedades cardiovasculares, diabetes tipo 2 y distintos tipos de cáncer, ...

Los fabricantes europeos de medicamentos como Ozempic y productos para el cuidado de la piel como Cetaphil han expresado su ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday ...

Estimación del precio real de una acción basada en modelos de valoración como el flujo de caja descontado, los múltiplos de valoración por pares y los modelos de descuento de dividendos.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.